Browsing by Author "Ucgul A.Y."

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    Scopus
    Descemet’s membrane area and posterior corneal power may predict the Descemet membrane folds after deep anterior lamellar keratoplasty in patients with advanced keratoconus
    (2021-12-01) Ozgur A.; Ucgul A.Y.; Cubuk M.O.; Onat E.; Ceylanoglu K.S.; Aydın B.; Yuksel E.
    Aims: To investigate possible predictive topographic characteristics for the development of Descemet’s membrane (DM) folds after the uneventful deep anterior lamellar keratoplasty (DALK). Methods: A retrospective study included 56 eyes of 56 consecutive patients who underwent uneventful DALK using the big-bubble technique to treat advanced keratoconus. At baseline and each visit, best-corrected logMAR visual acuity (BCVA), slit-lamp findings, endothelial cell density, topographic parameters were recorded. DM area is calculated using morphogeometric modelling. Results: Twelve (21.4%) of them exhibited DM folds, whereas the remaining 44 (78.6%) did not exhibit any DM folds after the surgery. The mean follow-up time was 36.3 ± 16.7 (range, 12–71) months. The mean posterior corneal power was − 13.8 ± 0.6 D in patients with DM folds, whereas − 13.0 ± 0.8 D in those without DM folds (p = 0.016). The mean DM area was 53.6 ± 2.3 (50.9–57.9) mm2 in patients with DM folds, whereas 51.6 ± 1.7 (47.1–53.9) mm2 in those without DM folds (p = 0.001). The ROC curve showed that two best cut-off value for the posterior corneal power and DM area were 13.75 D and 53.8 mm2, respectively, to predict the occurrence of DM folds. Conclusion: DALK surgery seems to cause DM folds in patients with large DM area and high posterior corneal power.
  • No Thumbnail Available
    Scopus
    Topical cyclosporine a (0.05%) treatment in dry eye patients: a comparison study of Sjogren’s syndrome versus non-Sjogren’s syndrome
    (2021-04-01) Cubuk M.O.; Ucgul A.Y.; Ozgur A.; Ozulken K.; Yuksel E.
    Purpose: To evaluate the clinical effect of topical cyclosporine A (CsA) (0.05%) on dry eye patients with Sjogren’s syndrome (SS) and non-Sjogren’s syndrome (NSS). Method: This retrospective comparative study includes the dry eye (DE) patients who were treated with topical CsA. DE patients were divided into two groups as follows: DE with Sjogren’s syndrome (DE-SS) and DE with Non-Sjogren’s syndrome (DE-NSS). Dry eye parameters were recorded at baseline and each visit. Results: Schirmer’s test 1 scores were 2.7 ± 0.5 mm at baseline and 3.5 ± 0.7 mm at 12th month in DE-SS, 2.9 ± 0.7 mm at baseline and 9.5 ± 0.7 mm in DE-NSS groups at 12th month. Mean ST score was higher in DE-NSS group than DE-SS group at sixth and 12th months of the treatment (both p = 0.001). Tear break-up time score showed a significant improvement in DE-NSS group, and it was lower in DE-NSS group than DE-SS group group at sixth and 12th months of the treatment (p = 0.044 and 0.027, respectively). Mean OSDI score was lower in DE-NSS group than DE-SS group at sixth and 12th months of the treatment (p = 0.030 and 0.032, respectively). Conclusion: Topical CsA seems to be more effective in the treatment of the DE-NSS.